Alpha1 antitrypsin deficiency (AATD) is a hereditary disorder, associated with the lack or deficiency of alpha 1 antitrypsin in the blood, a protein that helps in the proper and healthy functioning of the lungs. The prevalence of Alpha 1 antitrypsin deficiency varies according to the origin of the population. As per DelveInsight, in 2017, the total number of AATD prevalent cases in the 6 MM (the US, and EU5 (Germany, France, Spain, Italy and the UK)) was found to be 175,009.
The Alpha 1 Antitrypsin Deficiency Treatment market appears to be firm as some of the key therapies are expected to set their foot in the AATD market in the next decade. The major pharmaceutical players in the Alpha-1 Antitrypsin Deficiency market such as Grifols, Takeda, GSK, AstraZeneca, Boehringer Ingelheim, Pfizer, Shire, LFB, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, Mereo BioPharma, Dicerna Pharmaceuticals, Inhibrx, Teva Pharmaceuticals, among others, are diligently involved in the development of therapies with the aim to slow down and prevent serious lung damages and associated complications.
For more detailed information, visit: Alpha-1 Antitrypsin Deficiency Therapeutics Market